Primary Prevention Of Coronary Heart Disease — Patent Landscape

Aggregated US Orange Book patent estate across every approved drug for primary prevention of coronary heart disease. 5 active patents protecting 1 drugs from 1+ originators. First major cliff: 2037. Daily refresh.

1
Approved drugs
5
Active US patents
61/100
Avg vulnerability
—
Annual revenue covered

Originators in Primary Prevention Of Coronary Heart Disease

Companies holding active patents on drugs approved for this indication. Click through to each company's full patent dashboard.

Pfizer 5 patents

Cliff calendar — next 15 years

Patent expiries per year across all drugs treating primary prevention of coronary heart disease. Each bar = one year. Y-axis scaled to peak year (5 patents).

5
37

Approved drugs ranked by patent estate

Drug Originator Active patents Avg vuln Revenue First cliff
Lipitor
Atorvastatin Calcium
 Pfizer 5 61 — 2037-06-07

Most attackable patents

Highest vulnerability scores in the indication — paragraph IV / IPR / design-around candidates.

Patent Drug Type Vuln Expiry
11925704 Lipitor method of use 75 2037-06-07
11654106 Lipitor method of use 70 2037-06-07
12370136 Lipitor formulation 55 2037-06-07
12168069 Lipitor formulation 55 2037-06-07
11369567 Lipitor formulation 50 2037-06-07

Strongest defences

Lowest vulnerability scores — pillars of the indication's IP fortress.

Patent Drug Type Vuln Expiry
11369567 Lipitor formulation 50 2037-06-07
12370136 Lipitor formulation 55 2037-06-07
12168069 Lipitor formulation 55 2037-06-07
11654106 Lipitor method of use 70 2037-06-07
11925704 Lipitor method of use 75 2037-06-07

Related